Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients

Pancreas

Volumn 14, Issue 3, 1997, Pages 222-228

  Militello, Carmelo ^a,c   Sperti, Cosimo ^a   Di Prima, Franco ^b   Pedrazzoli, Sergio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Cittadella Hospital   (Italy)

^c Istituto di Semeiotica Chirurgica   (Italy)

Author keywords

A receptor antagonist; Cholecystokinin; Loxiglumide; Pancreatic cancer

Indexed keywords

CHOLECYSTOKININ A RECEPTOR ANTAGONIST; LOXIGLUMIDE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PANCREAS CANCER; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030965547     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199704000-00002     Document Type: Article

References (20)

1. Gudyonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284-303.
2. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-63.
3. Arbuck SG. Chemotherapy for pancreatic cancer. Clin Gastroenterol 1990;4:953-68.
4. Dobelbower RR, Bronn DG. Radiotherapy in the treatment of pancreatic cancer. Clin Gastroenterol 1990;4:969-83.
5. Townsend CM Jr, Singh P, Thompson JC. Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 1986;91:1002-6.
6. Lamers CBHW, Jansen JBMJ. Role of gastrin and cholecystokinin in tumors of gastrointestinal tract. Eur J Cancer Clin Oncol 1988;24:267-73.
7. Townsend CM Jr, Franklin RB, Watson LC, et al. Stimulation of pancreatic cancer growth by cerulein and secretin. Surg Forum 1981;32:228-9.
8. Lhoste EF, Longnecker DS. Effect of bombesin and cerulein on early stages of carcinogenesin induced by azaserine in the rat pancreas. Cancer Res 1987;47:3273-7.
9. Sperti C, Militello C, Rovati LC, et al. Effect of cholecystokinin analogue cerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. J Surg Oncol 1994;57:11-6.
10. Setnikar I, Bani M, Cereda R, et al. Pharmacological characterization of a new potent and specific nonpolipeptidic cholecystokinin antagonist. Arzneim Forsch Drug Res 1987;37: 703-7.
11. Povoski SP, Zhou W, Longnecker DS, et al. Growth of azaserine-induced putative preneoplastic nodules in the rat pancreas is mediated specifically by way of cholecystokinin - A receptor Ann NY Acad Sci 1994;713:439-41.
12. Setnikar I, Chistè R, Makonec F, et al. Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Arzneim Forsch 1988;38:716-20.
13. Chua ASB, Bekkering M, Rovati LC, et al. Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in non-ulcer dyspepsia. Ann NY Acad Sci 1994;713:451-3.
14. Hermanek P, Sobin LH. UICC: TNM classification of malignant tumors, 4th ed. New York: Springer, 1987.
15. Malesci A, De Fazio C, Festorazzi S, et al. Dose-response effects of oral loxiglumide on postprandial gall-bladder emptying in man. Arzneim Forsch Drug Res 1992;42:1359-62.
16. Abbruzzese JL, Gholson CF, Daugherty K, et al. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 1992;7: 165-71.
17. Bell RH, Kuhlmann ET, Jensen RT, et al. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas. Cancer Res 1992;52:3295-9.
18. Nio Y, Tsubono M, Morimoto H, et al. Loxiglumide (CR 1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice. Cancer 1993;72:3599-606.
19. Axelson J, Ihse I, Hakanson R. Pancreatic cancer: the role of cholecystokinin? Scand J Gastroenterol 1992;27:993-8.
20. Herrington MK, Adrian TE. On the role of cholecystokinin in pancreatic cancer. Int J Pancreatol 1995;17:121-38.